Coeptis Therapeutics Hldgs Inc (COEP)

$12.07 -0.41 (-3.29%)
Market Cap 67.42M
Revenue (ttm) 0.00
Net Income (ttm) -10.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.01
Volume 42,300
Avg Vol 54,398
Day's Range N/A - N/A
Shares Out 5.34M
Stochastic %K 46%
Beta -0.49
Analysts Strong Buy
Price Target $3.00

Company Profile

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, natural killer cell therapy technology. Its product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-rela...

Industry: Biotechnology
Sector: Healthcare
Phone: 724 934 6467
Address:
105 Bradford Road, Suite 420, Wexford, United States
RyGuy5000
RyGuy5000 Mar. 12 at 8:44 PM
$COEP i just dont like complete silence.
0 · Reply
AllAmerican82ndAirborne
AllAmerican82ndAirborne Mar. 12 at 7:49 PM
$COEP keep those bids
0 · Reply
PS600REVX
PS600REVX Mar. 12 at 6:20 PM
$COEP Lia Wong, you hopping on? I mean in the buy some shares way 😳
1 · Reply
PS600REVX
PS600REVX Mar. 12 at 5:54 PM
$COEP I know we're all getting impatient here, but adding with my EONR profits so I don't mind these prices for the rest of this week. That's how it's supposed to work. Sorry, My selfish post of the week.
0 · Reply
AllAmerican82ndAirborne
AllAmerican82ndAirborne Mar. 12 at 2:08 PM
$COEP could see low 11’s. Have your bids in place
1 · Reply
LiaWong1998
LiaWong1998 Mar. 12 at 1:25 PM
$COEP very low float feel here so quiet accumulation can turn into a sharp squeeze
0 · Reply
Stokroulette
Stokroulette Mar. 12 at 12:36 PM
$COEP so boring
1 · Reply
Ollie41295
Ollie41295 Mar. 12 at 11:18 AM
$COEP with all this time taken with the merger , I really hope we see 30 here
1 · Reply
crookedtomlee
crookedtomlee Mar. 11 at 4:44 PM
$COEP added 7000 shares lets go retards
1 · Reply
AllAmerican82ndAirborne
AllAmerican82ndAirborne Mar. 11 at 4:06 PM
$COEP oh come on you could have filled my 11.50s!! 🤬
1 · Reply
Latest News on COEP
Coeptis Receives Shareholder Approval Towards Z Squared Merger

Feb 5, 2026, 4:00 PM EST - 5 weeks ago

Coeptis Receives Shareholder Approval Towards Z Squared Merger

Coeptis Therapeutics S-4 Declared Effective by SEC, Proxy Mailing Begins in Anticipation of the Merger Transaction with Z Squared

Jan 6, 2026, 8:19 AM EST - 2 months ago

Coeptis Therapeutics S-4 Declared Effective by SEC, Proxy Mailing Begins in Anticipation of the Merger Transaction with Z Squared

Vanderbilt Report: Coeptis Shows How Biotech Can Fund Itself While Innovating

Sep 23, 2025, 8:00 AM EDT - 6 months ago

Vanderbilt Report: Coeptis Shows How Biotech Can Fund Itself While Innovating

Coeptis (COEP) Extinguishes Convertible Note with YA II PN, Ltd

Jul 22, 2025, 8:36 AM EDT - 8 months ago

Coeptis (COEP) Extinguishes Convertible Note with YA II PN, Ltd

Coeptis (COEP) Announces Filing of Registration Statement on Form S-4 with SEC in Connection with Proposed Transaction with Z Squared

Jun 26, 2025, 8:34 AM EDT - 9 months ago

Coeptis (COEP) Announces Filing of Registration Statement on Form S-4 with SEC in Connection with Proposed Transaction with Z Squared

Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology

May 28, 2025, 8:28 AM EDT - 10 months ago

Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology

Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement

Apr 25, 2025, 8:33 AM EDT - 11 months ago

Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement

COEPTIS Partners with NexGenAI Solutions Group to Launch New AI Co-Working Hub in India, Driving Global Innovation in Technology

Apr 17, 2025, 8:38 AM EDT - 11 months ago

COEPTIS Partners with NexGenAI Solutions Group to Launch New AI Co-Working Hub in India, Driving Global Innovation in Technology

Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline

Mar 11, 2025, 8:34 AM EDT - 1 year ago

Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline

COEPTIS' NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan

Mar 7, 2025, 8:37 AM EST - 1 year ago

COEPTIS' NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan

NUBURU Partners With COEPTIS NexGenAI Affiliates Network to Drive Innovation in AI and Robotics as Part of Its Transformation Plan

Mar 6, 2025, 8:00 AM EST - 1 year ago

NUBURU Partners With COEPTIS NexGenAI Affiliates Network to Drive Innovation in AI and Robotics as Part of Its Transformation Plan

BURU

COEPTIS' NexGenAI Partners with Arketyp Valu to Revolutionize Digital Engagement on the Verus Network

Feb 20, 2025, 9:00 AM EST - 1 year ago

COEPTIS' NexGenAI Partners with Arketyp Valu to Revolutionize Digital Engagement on the Verus Network

COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing

Feb 20, 2025, 7:27 AM EST - 1 year ago

COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing

COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent Startups

Feb 13, 2025, 8:39 AM EST - 1 year ago

COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent Startups

COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration

Feb 6, 2025, 8:08 AM EST - 1 year ago

COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration

Coeptis Therapeutics Holdings Becomes COEPTIS: Embracing a Future of Technology and Innovation

Jan 30, 2025, 8:27 AM EST - 1 year ago

Coeptis Therapeutics Holdings Becomes COEPTIS: Embracing a Future of Technology and Innovation

Coeptis Therapeutics Leverages Artificial Intelligence and Blockchain for Next-Generation Innovation

Jan 23, 2025, 8:09 AM EST - 1 year ago

Coeptis Therapeutics Leverages Artificial Intelligence and Blockchain for Next-Generation Innovation

Coeptis Therapeutics Regains Compliance with Nasdaq Listing Rule 5550(a)(2)

Jan 22, 2025, 8:00 AM EST - 1 year ago

Coeptis Therapeutics Regains Compliance with Nasdaq Listing Rule 5550(a)(2)

Coeptis Therapeutics Announces First Customer Adoptions of its NexGenAI Marketing Platform

Jan 7, 2025, 8:00 AM EST - 1 year ago

Coeptis Therapeutics Announces First Customer Adoptions of its NexGenAI Marketing Platform

Coeptis Therapeutics Announces Reverse Stock Split

Dec 27, 2024, 8:15 AM EST - 1 year ago

Coeptis Therapeutics Announces Reverse Stock Split

Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies

Dec 26, 2024, 8:15 AM EST - 1 year ago

Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies

Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies

Dec 12, 2024, 8:00 AM EST - 1 year ago

Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies

Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries

Dec 3, 2024, 8:15 AM EST - 1 year ago

Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries

Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development

Nov 7, 2024, 8:07 AM EST - 1 year ago

Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development

Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use

Oct 24, 2024, 8:07 AM EDT - 1 year ago

Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use

Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy

Oct 15, 2024, 8:07 AM EDT - 1 year ago

Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy

Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Sep 19, 2024, 7:07 AM EDT - 1 year ago

Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to Shareholders

Sep 5, 2024, 8:07 AM EDT - 1 year ago

Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to Shareholders

Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering

Jun 20, 2024, 8:47 AM EDT - 1 year ago

Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering

Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting

May 30, 2024, 8:47 AM EDT - 1 year ago

Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting

Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024

May 8, 2024, 8:47 AM EDT - 2 years ago

Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024

Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting

May 2, 2024, 8:47 AM EDT - 2 years ago

Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting

Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award

Apr 2, 2024, 8:47 AM EDT - 2 years ago

Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award

Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK

Feb 26, 2024, 9:00 AM EST - 2 years ago

Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK

Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections

Feb 7, 2024, 7:30 AM EST - 2 years ago

Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections

Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024

Jan 4, 2024, 7:30 AM EST - 2 years ago

Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024

Coeptis Therapeutics to Present at the Emerging Growth Conference

Dec 4, 2023, 7:30 AM EST - 2 years ago

Coeptis Therapeutics to Present at the Emerging Growth Conference

Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023

Oct 31, 2023, 9:01 AM EDT - 2 years ago

Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023

Coeptis Therapeutics Announces $2 Million Private Placement

Oct 24, 2023, 8:30 AM EDT - 2 years ago

Coeptis Therapeutics Announces $2 Million Private Placement

Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology

Oct 11, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology

Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies

Oct 9, 2023, 9:15 AM EDT - 2 years ago

Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies

Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Oct 4, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa

Sep 27, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa

Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection

Sep 14, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection

Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment

Sep 11, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment

Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer

Aug 30, 2023, 1:00 PM EDT - 2 years ago

Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer

Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics

Aug 17, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics

Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic

Aug 1, 2023, 8:00 AM EDT - 2 years ago

Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic

Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering

Jun 16, 2023, 4:00 PM EDT - 2 years ago

Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering

RyGuy5000
RyGuy5000 Mar. 12 at 8:44 PM
$COEP i just dont like complete silence.
0 · Reply
AllAmerican82ndAirborne
AllAmerican82ndAirborne Mar. 12 at 7:49 PM
$COEP keep those bids
0 · Reply
PS600REVX
PS600REVX Mar. 12 at 6:20 PM
$COEP Lia Wong, you hopping on? I mean in the buy some shares way 😳
1 · Reply
PS600REVX
PS600REVX Mar. 12 at 5:54 PM
$COEP I know we're all getting impatient here, but adding with my EONR profits so I don't mind these prices for the rest of this week. That's how it's supposed to work. Sorry, My selfish post of the week.
0 · Reply
AllAmerican82ndAirborne
AllAmerican82ndAirborne Mar. 12 at 2:08 PM
$COEP could see low 11’s. Have your bids in place
1 · Reply
LiaWong1998
LiaWong1998 Mar. 12 at 1:25 PM
$COEP very low float feel here so quiet accumulation can turn into a sharp squeeze
0 · Reply
Stokroulette
Stokroulette Mar. 12 at 12:36 PM
$COEP so boring
1 · Reply
Ollie41295
Ollie41295 Mar. 12 at 11:18 AM
$COEP with all this time taken with the merger , I really hope we see 30 here
1 · Reply
crookedtomlee
crookedtomlee Mar. 11 at 4:44 PM
$COEP added 7000 shares lets go retards
1 · Reply
AllAmerican82ndAirborne
AllAmerican82ndAirborne Mar. 11 at 4:06 PM
$COEP oh come on you could have filled my 11.50s!! 🤬
1 · Reply
Moneymachine67
Moneymachine67 Mar. 11 at 3:52 PM
$COEP how it this
0 · Reply
PS600REVX
PS600REVX Mar. 11 at 2:53 PM
$COEP anddddd more anemic volume shorting. Still just a matter of time. 😴😳
1 · Reply
AllAmerican82ndAirborne
AllAmerican82ndAirborne Mar. 11 at 2:26 PM
$COEP
0 · Reply
newdmontheblock
newdmontheblock Mar. 10 at 6:43 PM
$COEP launchpad prepped. Let’s light it.
0 · Reply
Stokroulette
Stokroulette Mar. 10 at 6:04 PM
$COEP get ready for the bear knockers , always a good sign, mark this post with all the fake posts about how bad this stock sucks!! See ya all on the other side $$$$
1 · Reply
PS600REVX
PS600REVX Mar. 10 at 3:21 PM
$COEP shorted heavily yesterday I assume and probably didn't cover. Let's roll em
0 · Reply
YuenglingSwing
YuenglingSwing Mar. 10 at 3:09 PM
$COEP get ready and load more if you can. $DOGE.X taking off 💸💸💸💸
0 · Reply
PS600REVX
PS600REVX Mar. 10 at 2:10 PM
$COEP back to huge volume !!!🥴
0 · Reply
Mibl
Mibl Mar. 10 at 1:34 PM
$COEP $DOGE.X drop the merge closing PR!
0 · Reply
kobramaximus
kobramaximus Mar. 10 at 11:38 AM
$COEP
0 · Reply
stinkstankstonc
stinkstankstonc Mar. 10 at 11:37 AM
$COEP 0$ according to ST this morning huh?
0 · Reply
Fluteman_Greg
Fluteman_Greg Mar. 10 at 10:41 AM
$COEP More Info for watchlisten who doesn't seem to be able to do his own research. " Z Squared's $660 million operational valuation, anchored to 9800 physical ASIC units with " VERIFIED DOMESTIC HOSTING AGREEMENTS ", reflects tangible asset backing that provides a floor valuation framework independent of near term asset price movements." Verified Domestic Hosting Agreements.......Do you get that, Watchlisten? That means the minging units have a home with existing electric demand agreements.
0 · Reply